The objective of this research is to determine if the investigational drug SR141716 (Rimonabant) decreases voluntary ethanol consumption in humans. The study population will be comprised of non-treatment seeking volunteers, who normally consume between 20 and 40 alcohol drinks per day. Study volunteers will receive either placebo or SR141716 three weeks prior to participating in an alcohol self-administration experiment conducted in a controlled environment. Following baseline psychological and endocrine measures, the volunteer's breath alcohol level will be raised to 0.03 g/dl. Over the next two-hour period, the volunteer will have the opportunity to consume up to eight drinks or receive a monetary reward for each drink not consumed. Rimonabant was made available to NIAAA in August 2004. To date three participants have completed the protocol. Six additional participants are scheduled for participation. Study remains blinded.

Agency
National Institute of Health (NIH)
Institute
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Type
Intramural Research (Z01)
Project #
1Z01AA000208-02
Application #
6983095
Study Section
(LCS)
Project Start
Project End
Budget Start
Budget End
Support Year
2
Fiscal Year
2004
Total Cost
Indirect Cost
Name
Alcohol Abuse and Alcoholism
Department
Type
DUNS #
City
State
Country
United States
Zip Code